[{"id":"67a7cc8f-4495-4593-a5ec-9a4e0b7286d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02414269","created_at":"2021-01-18T11:32:05.371Z","updated_at":"2024-07-02T16:35:02.997Z","phase":"Phase 1/2","brief_title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","source_id_and_acronym":"NCT02414269","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-17"}]